JP6184960B2 - メラトニンの新規用途 - Google Patents

メラトニンの新規用途 Download PDF

Info

Publication number
JP6184960B2
JP6184960B2 JP2014530214A JP2014530214A JP6184960B2 JP 6184960 B2 JP6184960 B2 JP 6184960B2 JP 2014530214 A JP2014530214 A JP 2014530214A JP 2014530214 A JP2014530214 A JP 2014530214A JP 6184960 B2 JP6184960 B2 JP 6184960B2
Authority
JP
Japan
Prior art keywords
melatonin
dietary supplement
symptoms
sublingual
hangover
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014530214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526488A (ja
Inventor
ラスーリアン，ダリウス
Original Assignee
ラスーリアン，ダリウス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラスーリアン，ダリウス filed Critical ラスーリアン，ダリウス
Publication of JP2014526488A publication Critical patent/JP2014526488A/ja
Application granted granted Critical
Publication of JP6184960B2 publication Critical patent/JP6184960B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014530214A 2011-09-16 2012-09-13 メラトニンの新規用途 Active JP6184960B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11181683.1 2011-09-16
EP20110181683 EP2570126B1 (en) 2011-09-16 2011-09-16 Use of melatonin for treating acute alcohol intoxication
PCT/EP2012/067933 WO2013037883A1 (en) 2011-09-16 2012-09-13 New use of melatonine

Publications (2)

Publication Number Publication Date
JP2014526488A JP2014526488A (ja) 2014-10-06
JP6184960B2 true JP6184960B2 (ja) 2017-08-23

Family

ID=46851981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530214A Active JP6184960B2 (ja) 2011-09-16 2012-09-13 メラトニンの新規用途

Country Status (8)

Country Link
US (1) US10179122B2 (ru)
EP (1) EP2570126B1 (ru)
JP (1) JP6184960B2 (ru)
CN (1) CN103813791B (ru)
AU (1) AU2012307430B2 (ru)
CA (1) CA2848231C (ru)
RU (1) RU2633484C2 (ru)
WO (1) WO2013037883A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020118188A1 (en) * 2018-12-07 2020-06-11 Suman Ajay Compositions for aiding liver function

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2718020B1 (fr) 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
EP0867181A1 (en) 1997-03-26 1998-09-30 Franciscus Wilhelmus Henricus Maria Merkus Nasal melatonin composition
KR100257448B1 (ko) 1997-08-01 2000-07-01 박홍락 항암, 기관분화유도, 암세포전이 혈관형성억제, 항산화 및 숙취해소 작용을 하는 옻나무 추출물, 이의 제조방법 및 이를 포함하는 조성물
US20020048551A1 (en) * 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
UA55668A (ru) 2002-04-12 2003-04-15 Інститут Геронтології Академії Медичних Наук України Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста
JP2007510716A (ja) 2003-11-07 2007-04-26 オーキー ナチュラル カンパニー，リミテッド 木酢液より抽出したグアヤコール系成分及びシリンゴール系成分を含有する薬学的組成物
US20050164987A1 (en) 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality
RU2250778C1 (ru) 2004-02-26 2005-04-27 Мясников Дмитрий Николаевич Средство, снижающее неблагоприятные последствия острой алкогольной интоксикации
CN101166538B (zh) 2005-05-02 2011-05-18 Cj第一制糖株式会社 用于预防和治疗酒后病的组合物
GB2434099A (en) 2006-01-12 2007-07-18 Roger Coghill Very low dosage melatonin compositions and their use in the treatment of the adverse effects of exposure to electromagnetic fields and radiation
US20070298133A1 (en) 2006-06-23 2007-12-27 The Procter & Gamble Company Compositions and kits comprising a melatonin component and a flavanol component
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20100119601A1 (en) 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
CN101754753A (zh) 2007-05-24 2010-06-23 纽约市哥伦比亚大学托管会 褪黑素的持久释放配方
US8691297B2 (en) * 2010-09-01 2014-04-08 Nippon Suisan Kaisha, Ltd. Alcoholic injury mitigating agent

Also Published As

Publication number Publication date
RU2014115196A (ru) 2015-10-27
EP2570126B1 (en) 2014-03-26
AU2012307430B2 (en) 2017-08-31
US20150111941A1 (en) 2015-04-23
CA2848231C (en) 2019-12-31
EP2570126A1 (en) 2013-03-20
RU2633484C2 (ru) 2017-10-12
CN103813791B (zh) 2016-06-15
US10179122B2 (en) 2019-01-15
CN103813791A (zh) 2014-05-21
AU2012307430A1 (en) 2014-04-17
CA2848231A1 (en) 2013-03-21
WO2013037883A1 (en) 2013-03-21
JP2014526488A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
JP5513126B2 (ja) 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用
JP2014528474A5 (ru)
JP2008509224A5 (ru)
TW200534852A (en) 4-methylpyrazole formulations for inhibiting ethanol intolerance
KR102597910B1 (ko) 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
JP2013541583A (ja) 組み合わせ組成物
Gautam et al. Evaluation of the efficacy of methylprednisolone, etoricoxib and a combination of the two substances to attenuate postoperative pain and PONV in patients undergoing laparoscopic cholecystectomy: a prospective, randomized, placebo-controlled trial
JP6184960B2 (ja) メラトニンの新規用途
JP2019504040A (ja) 中等度〜重度のインフルエンザの処置
WO2004080414A2 (en) Composition and method for treating inflammations by reducing c-reactive protein
TW201249450A (en) Sweet tea olive extract and manufacturing method and use thereof, as well as the composition comprising the sweet tea olive extract for prevention or treatment of melancholia
WO2004017973A1 (ja) 統合失調症治療剤
TW200831072A (en) Non-steroidal anti-inflammatory drugs for cough
CN101085073A (zh) 桑叶杏仁口服液
CN109646438A (zh) 去甲乌药碱或其盐酸盐在制备治疗鼻炎药物中的应用
JPWO2019237054A5 (ru)
US11464756B1 (en) Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof
JP7034314B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
CN106728747A (zh) 一种治疗灰指甲的中医药物配方
WO2022018085A1 (en) Pde3 inhibitors for treating viral infections
RU2345763C1 (ru) Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин
WO2022126255A1 (en) Antioxidant nutritional supplement for immune system support
CN107648226A (zh) 一种治疗偏头痛的药物组合物及其制备方法
CN106728023A (zh) 一种治疗胆结石的中医药物配方
JP2006151987A (ja) ビタミンｃとカルシウムによる睡眠剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170726

R150 Certificate of patent or registration of utility model

Ref document number: 6184960

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250